Scientists at the University of Birmingham, UK, have shown that a novel low molecular weight dextran-sulphate, ILB® could play a key role in treating open angle glaucoma (OAG), a ...

First, high-molecular-weight iron dextran was removed from the market, and subsequently, low-molecular-weight iron dextran (InFed [Watson]) was released.

Low-molecular-weight iron dextran is one of the parenteral iron preparations administered to patients receiving erythropoietin therapy.

These included high–molecular-weight iron dextran, low–molecular-weight iron dextran, iron gluconate, iron sucrose (Venofer, Luitpold) and ferumoxytol (Feraheme, AMAG Pharmaceuticals).

Scientists at the University of Birmingham, UK, have shown that a novel low molecular weight dextran-sulphate, ILB could play a key role in treating open angle glaucoma (OAG), a neurodegenerative ...

The use of low-molecular-weight dextran as a clinical tool in the management of a number of conditions other than those cited suggests itself and may warrant clinical trial.

Chinese researchers have worked on using existing low molecular weight drugs to treat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes COVID-19 disease.

A low molecular weight dextran-sulphate could play a key role in treating open angle glaucoma, a neurodegenerative disease that affects over 70 million people worldwide and causes irreversible ...

Researchers showed that novel low molecular weight dextran-sulphate, ILB®, can normalise matrix deposition inside the eye and lower IOP in a pre-clinical model of human glaucoma, paving the way ...

Cinti told FoodNavigator: “Until now, dextran - the one with low molecular weight and branched - was mainly utilised by pharma industry and with a high price. Our dextran, Nextdext, is a high ...